annb0t
Top 20
MELBOURNE, Australia, Sept. 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma multiforme (GBM). (PRNewsfoto/Telix Pharmaceuticals Limited)
The primary objective of the IPAX-1 study was to evaluate the safety and tolerability profile of intravenou...
>>> Read more: Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data
The primary objective of the IPAX-1 study was to evaluate the safety and tolerability profile of intravenou...
>>> Read more: Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data
